Document:

The P65Oncofetal Protein as a Novel Tumor Marker in Detection of
                                Breast, Prostrate and Other Cancers  CSU 5-s6904

                                 Amendment No. 1
                               Research Agreement
                                     between
         The Board of Governors of the Colorado State University System
                 acting by and through Colorado State University
                                       and
                                Xpention Genetics

     This  Amendment is made and entered into by and between  Xpention  Genetics
hereinafter  referred  to as the  SPONSOR,  and the  Board of  Governors  of the
Colorado  State  University  System,   acting  by  and  through  Colorado  State
University, hereinafter referred to as UNIVERSITY.

NOW THEREFORE,
The  parties  mutually  agree  to  the  following  revisions  to  this  Research
Agreement:

Article 1 - Scope of Work The  University  agrees to perform for the Sponsor the
additional  research  described in the Scope of Work, Exhibit A1 attached hereto
and  incorporated by this reference,  under the direction and supervision of the
Principal  Investigator,   Dr.  Susan  Lana,  in  accordance  with  any  service
milestones or periodic deliverables specified on Scope of Work Attachment.

Article  2 - Term
This Agreement is extended to November 1, 2006

Article 3 -  Payment  The  Sponsor  agrees to pay the  University  for  research
performed  under  this  Agreement  in a fixed  price  amount as set forth in the
Budget Attachment, Exhibit B1 attached hereto and incorporated by reference. The
University  reserves  the right to  reallocate  funds  between  approved  budget
categories. Payment will be made in accordance with the schedule provided below:

         Fifty percent  (50%)  ($7,665)  upon  acceptance  of  agreement;  Forty
         percent  (40%)($6,132) mid-way through project (date: May 1, 2006); Ten
         percent (10%) ($1,533) upon submission of final report.

All other terms and conditions of this agreement remain the same.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
as of the date set forth herein by their duly authorized representatives.

The Board of Governors of the               Xpention Genetics
Colorado State University System,
acting by and through Colorado
State University

/s/ Lynn ????                               /s/ David Kittrell
------------------------------------        ------------------------------------

Director, ??? Programs       11/2/05        President                   10/26/05
------------------------------------        ------------------------------------
Title                         Date          Title                         Date

<PAGE>

                                                                      EXHIBIT A1

                             Description of Project

Specific Aims

Aim of this project is the  development of a molecular test for early  detection
of cancer in dogs.  This test will  target a genetic  marker  which  levels  are
greatly  increased in the early stages of cancer  development.  Using "Real Time
Fluorogenic PCR (F-PCR)"technology, this test will accurately measure level of "
P65 gene expression" during the different clinical stages of cancer development.
By comparing levels of P65 before,  during and after therapy it will be possible
to  determine  1) rate of response to cancer  treatment  2)  prognosis  outlook.
Several studies using other genetic markers have shown that these two parameters
are of paramount importance in deciding whether a specific chemotherapy protocol
should be continue or terminate because a poor long term outlook.

Technology Background

"Real Time Fluorogenic PCR" assay for P65

Previous  studies  performed  in canine lymph  sarcoma  showed that during early
stages  of tumor  development  level of P65 in the  blood  of  affected  animals
increases  up to 50 folds.  These  studies also showed that during the course of
chemotherapy levels of P65 return to normal if the animal successfully  responds
to the treatment.  Techniques  used during these studies are based on the use of
immunological  assays.   Several  limitation  exist  when  such  techniques  are
employed:  1) low  sensitivity  in detecting P65 levels;  2) lack of correlation
between the presence of antibodies in serum and stages of tumor progression;  3)
antibodies  are detected at a later stage of tumor  progression  when compare to
changes  in  genetic  levels of the  target  gene.  F- PCR  overcomes  the above
limitations  making it possible to perform  much  earlier  diagnosis  of cancer.
F-PCR  is the  most  sensitive  technology  available  to  date  to  detect  and
quantitate  genetic  levels in a variety of  tissues.  F-PCR will be employed to
develop a clinical assay for P65 detection in blood cells of dogs  lymphosarcoma
and other type of  cancer.  This is the first  cancer  test that will be able to
detect the presence of a genetic cancer marker in circulating  cells rather than
tissues.  The  implications  of this  approach  are of  paramount  importance:1)
eliminates  the  need  of  invasive  procedures  such  biopsies  or  explorative
surgery;2)  allows more  frequent  assay  screenings  cutting  waiting  time; 3)
reduces  diagnostics errors often present when  histopathology is performed;  4)
allows correct correlation between tumor stage and chemotherapy  response and 5)
allows faster determination of rate of success to chemotherapy.

Assay Development

We anticipate a 12 month period in order to complete the  development of the P65
molecular  assay for detection of cancer in dogs.  Listed below is a description
of the developmental phases

Phase I

- Development of RNA extraction protocol from canine blood samples
- Designing of the P65 oligonucleotides primers and FAM probe

<PAGE>

- Designing of GAPDH oligonucleotides primers and VIC probe

Phase II

- Endogenous control calibration
- Baseline determination of P65 expression
- Delta Ct correlation

Phase III

- Multiplex assay development

Phase IV

- Assay validation

Scope of work to be completed by Animal Cancer Center, Colorado State University
under the  supervision of Dr Susan Lana.  Blood samples will be obtained from 60
canine patients with cancer at the time of initial  diagnosis.  Informed consent
will be  obtained  from each pet owner as well as ACUC  approval.  A variety  of
tumor types will be represented as agreed upon with the sponsor. Samples will be
collected into specified  tubes  (provided by the sponsor) for RNA  preservation
and will be processed according to procedures  provided.  Samples will be frozen
and stored and sent in batches to the  sponsor.  The time  required  to complete
this  portion of the  project is  dependant  on the  clinical  case load and the
tumors types  selected by the sponsor.  It is anticipated 6 to 10 months will be
required.

Budget justification
Attached  (appendix 1) is a budget for 60 samples based on a per sample  charge.
This charge includes supplies,  personnel, and other costs associated with blood
collection, processing and storage.

<PAGE>

                                                                      EXHIBIT B1

Budget for molecular detection of p65 in canine blood samples

Sample cost
         $175 per sample, 60 samples requested                         $10,500

Indirect cost
         Non clinical trial rate at CSU 46%                            $4830

Total                                                                  $15,330EXHIBIT 10.1

The Agreement ("Agreement") is entered into December 18, 2005 by the following
parties:

     Party A: Wang Yuan Feng and Zhang Yu Kun, (the shareholders of Beijing Dong
Fang Zheng Yi Film & TV Communication Co., Ltd. and Beijing Dong Fang Zheng Yi
Film Investment Consulting Co., Ltd.)

     Address: Room 1708, Academy International Building No.1, Zhi Chun Road,
Haidian District, Beijing, 100083, China

     Tel: 8610-82330889

     Facsimile: 8610-82330886

     Representative:       Wang Yuan Feng   Nationality: Chinese

     Party B: Navistar Communication Holding, LTD

     Contact Address: 4001 S DECATUR BLVD, SUITE 37-218 LAS VEGAS NV 89103

     Tel: 1.917.417.0538

     Facsimile: 212.310.1682

     Representative:       Don Lee                   Nationality:  U.S.A.

     (1)  Party A is the sole shareholder of Beijing Dong Fang Zheng Yi Film &
          TV Communication Co., Ltd. and Beijing Dong Fang Zheng Yi Film
          Investment Consulting Co., Ltd. (Referred to collectively as "Dong
          Fang" hereafter), legally registered limited liability companies
          established according to the laws of the People's Republic of China
          ("China") laws, who authorizes its representative Wang Yuan Feng to
          represent Dong Fang to sign this Agreement; Party B is a legally
          registered limited liability company registered in U.S.A.

     (2)  In Accordance with The Company Law of China, The Contract Law of China
          as well as other prevailing laws and regulations, Part B decides to
          take operation control of and make investment in Dong Fang, and invest
          in Dong Fang directly or indirectly through one of Party B's
          subsidiaries.

<PAGE>
1.   Representations and Warranties

     1.1. The representations and warranties jointly made by the both parties
are listed as follows:

     (1)  The both parties have all the relevant legal right and capacity and
          are qualified for signing and implementation of this Agreement, and at
          the same time, the signing and implementation of this Agreement will
          not violate any or all the legal documents such as regulations on the
          Company Regulation, Contract and Agreement which imposes certain
          restrictions on it.

     (2)  The both parties have already carried out all the required actions or
          will do so, to obtain the consent, approval, authorization and permit
          required by signing and implementation of this Agreement.

     (3)  In keeping with the principles of reliability and creditability and
          responsibility, both parties will make utmost efforts to work in close
          cooperation to promote the smooth implementation of this Agreement.
          The parties will follow the principles set forth within this
          Agreement, and will not impede the implementation of this Agreement.

     The representations and warranties of Party A

     1.2 The representations and warranties that Party A makes to Party B are
listed as follows:

          (1)  All the materials having been or to be provided by Party A are
               authentic, complete, accurate with no misleading information.

          (2)  The registered capital of Dong Fang has been fully contributed;
               Dong Fang owns the legal ownership and use rights of the total
               assets.

                                       2
<PAGE>
          (3)  Dong Fang has obtained necessary rights and permits,
               authorizations, approvals and consent required for media content
               production and business operation. The business scope of Dong
               Fang does not go beyond the operational scope approved as well as
               the rules of its articles.

          (4)  Its financials statements as audited by its auditing firm
               according to the US GAAP are true and correct and fairly
               represent the operation results of Dong Fang.

          (5)  Party A shall disclose all the mortgage of assets, sponsor and
               related lawsuits and arbitration as well as administrative
               penalties to which Party A is subject.

          (6)  Additional Representations and Warranties: There will be no
               material change in the contributed assets and debt of Dong Fang
               and Party A will maintain normal cash flow for the operational
               activities;

     1.3 The representations and warranties that Party B makes to Party A are
listed as follows:

          (1)  All the materials having been or to be provided to party A are
               authentic, timely and complete.

          (2)  Party B recognizes all the contracts entered into before this
               Agreement, and will cause the Joint Venture to duly fulfill the
               implementation of this Agreement.

     2.   Operation Control and Investment

     2.1 The scope of the capital assets of this cooperation refers to the total
assets appearing on the financials of Dong Fang.

     2.2. As of the date of this Agreement, Party B shall assume the full
operation control of Party A, including without limitation all aspects of Dong
Fang's business operation, production, distribution and sale of products and
shall have the complete power to appoint and change Dong Fang's top management
staff and executives. Party B shall also nominate majority of Dong Fang's board
members including its chairman.

                                       3
<PAGE>
     2.3. Party B agrees to inject additional funding into Dong Fang either
directly or indirectly. After the completion of investment from Party B, Dong
Fang will become a subsidiary of Party B with Party B holds 70% of the total
equity and Party A holds 30% of the total equity of Dong Fang.

     2.4  Standstill

     Party A shall not enter into any discussion of capital contribution and
cooperation with any third party without the consent of Party B and shall avail
itself for the acquisition transaction as provided in Section 2.2 above.

     3.   Arrangement of the transaction

     3.1. Party B shall make a total capital contribution of US$1,600,000 in
cash to Dong Fang in a format agreed to by the parties within the next 180 days.

     3.2. Party B or its affiliated company shall make a payment of US$800,000
in cash to Mr. Wang Yuan Feng no later than 180 days after the signing of this
Agreement.

     3.3. A total of US$6,2 00,000 worth of shares are going to be issued to
Party A and their designees. The total shares are valued at US $6,200,000 at
$1.00 per share to be paid to Party A within 10 days upon the signing of this
Agreement.

     4.   Finance and taxation

     The transaction price set does not include the undistributed profits of
Dong Fang before the ownership has transferred, which shall be owned by the
original shareholders of Dong Fang. The specific definition of the undistributed
profits of Dong Fang before the ownership has transferred is that the
undistributed profits of Dong Fang on the day party A and Party B sign the
Agreement and jointly recognized by the both parties plus the generated
reasonable profits during the period of the day the Agreement is singed to the
day the ownership has transferred to Party B.

     5.   Others

                                       4
<PAGE>
     5.1. This Agreement is not allowed to be terminated on unilaterally.

     5.2. If any of the parties breaches the Agreement, the non-breaching party
has rights to ask the other party for compensations due to breach of Agreement.

     5.3. If any dispute arises between the two parties, the dispute shall be
negotiated and settled within 30 working days. If the negotiation fails, the two
parties can seek arbitration as the exclusive remedy and such arbitration award
shall be final, exclusive, binding and enforceable against the parties. The
arbitration shall be held in Hong Kong before the arbitral tribunal under the
auspices of the Hong Kong Chamber of Commerce using its procedural rules.

     5.4. For issues fails to be mentioned in this Agreement, the two parties
may sign supplementary Agreement or attachment in writing, which forms effective
components of this Agreement with the same legal effect. 5.5. This Agreement is
in quadruplicate, with two copies held by each party. Party A: Authorized
representative:

     Party B:

     Authorized representative:

                                       5
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]